📊 Incidence & survival
~1 in 500 children develops cancer before 15y. 5-year survival now >80% in high-income countries (ALL ~90%, Wilms ~90%, Hodgkin >95%). Improvements due to risk-adapted therapy and supportive care.
🧬 Inherited predisposition & genetics
Li-Fraumeni (TP53), RB1 (retinoblastoma), APC (FAP), NF1, WT1 (Wilms), DICER1. Susceptibility genes: CHEK2, PALB2, BRCA2. Somatic mutations drive tumorigenesis.
🌍 Environmental factors
Ionising radiation (secondary cancers), chemotherapy (alkylators → leukemia), in utero radiation, Epstein-Barr virus (lymphoma), HIV (Kaposi), pesticides (limited evidence).
🔬 Diagnosis & markers
Pathology (gold standard), radiology (CT/MRI/US), biochemical markers (AFP, β-hCG, catecholamines, LDH), cytogenetics (translocations, ploidy), bone marrow aspirate (leukemia/lymphoma).
💊 Therapy & resistance
Multimodal: surgery, chemotherapy, radiotherapy, immunotherapy, HSCT. Drug resistance mechanisms: MDR1 (P-gp), altered drug targets (topoisomerase), DNA repair. Monitoring response: imaging (RECIST), MRD (flow/PCR).
⚠️ Late effects (survivorship)
Cardiomyopathy (anthracyclines), secondary malignancies (etoposide/alkylators, radiation), endocrine (GH deficiency, hypothyroidism, infertility), neurocognitive (cranial RT), psychosocial, dental, pulmonary.